Medivir spins out compound
Medivir AB and Epiphany Biosciences have signed a license agreement on MIV-606 (valomaciclovir), Phase II compound with potent activity against varicella zoster virus (VZV) and other viruses.Medivir will receive equity in Epiphany, milestone payments of up to $24.5m and royalty from worldwide sales except the Nordic countries where Medivir has retained the marketing rights.
Epiphany will be responsible for the further clinical development of MIV-606.
Phase IIa studies have shown MIV-606 to be efficacious and safe in patients with shingles, caused by the varicella zoster virus (VZV).
The market for zoster drugs is going to increase with the aging population according to the companies.
MIV-606 is also a potent inhibitor of other herpesviruses
increasingly imp-licated in various diseases such as mononucleosis, chronic fatigue syndrome, multiple sclerosis and the development of HIV/AIDS.
Medivir’s East of England headquarters is located at Chesterford Research Park in Essex.